Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Upadacitinib improved multiple immune-related conditions in one patient.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Derinat helps extend hair growth by reducing harmful molecules in skin cells.

Nilotinib can cause generalized keratosis pilaris.

Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.

Upadacitinib is effective and safe for treating severe alopecia areata in teens.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Erlotinib can cause hair loss as a side effect.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Upadacitinib may effectively treat alopecia areata without side effects.

Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Sorafenib often causes skin side effects, indicating effective cancer treatment.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

JAK inhibitors effectively treat skin conditions and topical forms are safer.

Peptides improve skin health and treatments for hair loss and pregnancy-related skin issues are evolving.

Recognizing and treating related skin conditions can improve atopic dermatitis management.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

The rash resolved after stopping ponatinib.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.